Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices
SA Egloff, X Cao, R Lachs, C Martin… - Leukemia & …, 2023 - Taylor & Francis
Management of higher-risk myelodysplastic syndromes (HR-MDS) is challenging in the real
world. We studied 200 patients with HR-MDS within a large US community hospital network …
world. We studied 200 patients with HR-MDS within a large US community hospital network …
Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms
AM Zeidan, K Perepezko, T Salimi… - Therapeutic …, 2024 - journals.sagepub.com
Background: Hypomethylating agents (HMAs) are guideline-recommended treatment for
higher-risk myelodysplastic syndromes/neoplasms (MDS). However, a prior survey of …
higher-risk myelodysplastic syndromes/neoplasms (MDS). However, a prior survey of …
Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine
E Takada, N Nakamura, Y Kaneda, K Fukuno… - Hematology …, 2024 - mdpi.com
Background: Azacitidine (AZA) is the standard treatment for patients with high-risk
myelodysplastic syndromes (MDS). The impact of skeletal muscle depletion (SMD), which is …
myelodysplastic syndromes (MDS). The impact of skeletal muscle depletion (SMD), which is …
[PDF][PDF] Patients' perspectives on oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes
A Zeidan, K Perepezko, T Salimi, T Washington… - Leuk Res, 2023 - ncoda.org
Background• Until recently, approved hypomethylating agents (HMAs) for higher-risk
myelodysplastic syndromes (HR-MDS) included intravenous (IV) decitabine and IV and …
myelodysplastic syndromes (HR-MDS) included intravenous (IV) decitabine and IV and …